Pneumonia Testing Market Segmentation:
End user Segment Analysis
The hospitals and clinics segment in the pneumonia testing market is projected to account for the highest share of 45.8% by the end of 2035. The segment’s growth is highly propelled by the latest advancements integrated in hospital and clinic facilities to combat diseases. According to an article published by the CDC in December 2024, 85% of acute care hospitals have readily implemented the Core Elements, in comparison to 41% over the past 10 years. Besides, the consumption of antibiotics, which are prescribed by medical professionals in hospitals and clinics, is also driving the market. However, 30% of suggested antibiotics in the U.S.-based hospitals are sub-optimal, thereby generating ineffective restrictions.
Product Segment Analysis
The molecular diagnostics (PCR-based) segment in the pneumonia testing market is anticipated to hold the second-highest share of 35.7% by the end of the forecast duration. The segment’s upliftment is effectively uplifted, owing to its increased accuracy for initiating differentiation in viral and bacterial pneumonia, which is essential for target-specific treatment. Additionally, the segment’s development is also attributed to a surge in the need for rapid diagnostic solutions, especially in reference labs and hospitals, wherein the PCR implementation has enhanced since 2022. Besides, government initiatives and progressions are also boosting the segment internationally.
Method Segment Analysis
The rapid antigen testing segment in the pneumonia testing market is expected to hold the third-highest share of 30.5% during the projected timeline. The segment’s development is highly driven by the ability to detect and evaluate asymptomatic and symptomatic SARS-CoV-2 infection. In this regard, a clinical study was conducted, which was published by NLM in July 2024. The study included 7,361 participants, of which 5,353 were asymptomatic, and with the utilization of the testing methods, the sensitivity rate was 93.4% for the symptomatic group and 62.7% for the remaining asymptomatic group, which later on improved by 79.0%, thus denoting the usefulness of the test.
Our in-depth analysis of the pneumonia testing market includes the following segments:
|
Segment |
Subsegments |
|
End user |
|
|
Product |
|
|
Method |
|
|
Technology |
|
|
Pathogen |
|
|
Test Setting |
|
